<?xml version="1.0" encoding="UTF-8"?>
<p>Tumor assessments were carried out on all target lesions identified at baseline by PET and CT scans after R‐High‐CHOP/CHASER and after LEED therapy completion (day 50‐63 after ASCT). In patients in CR after LEED therapy, tumor assessment was done every 6 months for 2 years and, thereafter, every year for the next 3 years. Tumor response was determined by the Revised Response Criteria for Malignant Lymphoma 2007.
 <xref rid="cas13719-bib-0019" ref-type="ref">19</xref> Toxicities were evaluated according to the NCI Common Terminology Criteria for Adverse Events version 3.0.
</p>
